Lantern Pharma (NASDAQ: LTRN) announced that the U.S. Food and Drug Administration raised no objections to proposed protocol amendments for the ongoing Phase 2 HARMONIC trial evaluating LP-300 in never-smokers with advanced non-small cell lung cancer (NSCLC) adenocarcinoma. The company said the FDA’s written response to its Type C meeting request provides a clearer regulatory path forward for the program, including a strategy focused on the EGFR exon 21 L858R-mutant never-smoker population, where emerging data suggest LP-300 may offer differentiated benefit in combination with standard chemotherapy following kinase inhibitor treatment failure.
This development is significant because it aligns the trial design with a specific genetic subset of patients who have limited treatment options after tyrosine kinase inhibitors (TKIs) fail. The FDA's support reduces regulatory uncertainty and potentially accelerates the development of LP-300, a cisplatin/ethacraplatin analog that targets DNA repair pathways. Lantern's precision oncology approach, powered by its proprietary RADR platform, aims to identify patients most likely to benefit, thereby improving trial efficiency and outcomes.
The HARMONIC trial is a key asset for Lantern, which is also developing LP-184 for pediatric CNS cancers through its subsidiary Starlight Therapeutics. The company recently commercialized withZeta.ai, a multi-agentic AI co-scientist platform, now available as a subscription-based research tool for the global biomedical community. This platform represents a new revenue stream and underscores Lantern’s commitment to leveraging artificial intelligence in drug development.
Investors should note that the FDA's feedback does not guarantee clinical success but removes a key hurdle in trial design. The company plans to incorporate the amendments and continue enrollment, with data readouts anticipated in the coming months. The focus on EGFR exon 21 L858R mutations could differentiate LP-300 from other therapies, as this population has shown resistance to standard treatments.
For more information on Lantern Pharma and its pipeline, visit the company's newsroom at https://ibn.fm/LTRN. The full press release is available here.